Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS

Sponsor
Linkoeping University (Other)
Overall Status
Completed
CT.gov ID
NCT02261142
Collaborator
University of Borås (Other), University Hospital, Linkoeping (Other), Sodra Alvsborgs Hospital (Other)
31
2
17

Study Details

Study Description

Brief Summary

Spasticity is a common consequence of injury to the central nervous system and can be a major problem in motor function and everyday activities. A method for treating spasticity that applies low-amplitude electrical stimulation through a garment with built-in electrodes, Mollii® (Elektrodress), has been developed. The garment is to be used in combination with individualized training and the stimulation is mainly given to antagonists of spastic muscles.

The general objective of this study is to evaluate the efficacy of and costs associated with the Mollii® treatment of spasticity due to stroke or cerebral palsy.

Primary objectives are;

  • to study whether treatment with the Mollii® improves function and activity

  • to evaluate the cost-effectiveness of the treatment, from both a health-care perspective and a societal perspective.

Secondary objectives are;

  • to study whether there are differences in treatment effect between the stroke and the Cerebral Palsy groups in a subgroup-analysis

  • to assess compliance with treatment

  • to report any adverse effects.

Condition or Disease Intervention/Treatment Phase
  • Device: Multifocal TENS garment (Mollii®)
N/A

Detailed Description

This study is designed as a double-blinded, randomized, cross-over trial (RCT). This part of the study takes 12 weeks (6 weeks of active treatment and 6 weeks of non-active treatment) and is followed by a wash-out period of 6 weeks. An uncontrolled,open phase starts after week 18, where patients are followed one year after inclusion.

30 participants with spasticity due to Stroke and Cerebral Palsy will be included.

Two centers are recruiting participants and are collecting data.

Outcome measures are chosen to reflect the different dimensions in the International Classification of Functioning, Disability and Health (ICF) and patient reported outcome measures (PROM).

Study Design

Study Type:
Interventional
Actual Enrollment :
31 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Evaluation of Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal Transcutaneous Electrical Stimulation, Through a Garment With built-in Electrodes in Combination With Training.
Study Start Date :
Sep 1, 2013
Actual Primary Completion Date :
Feb 1, 2015
Actual Study Completion Date :
Feb 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Multifocal TENS

Multifocal TENS given in the garment Mollii® (Elektrodress) 1 hour every second day together with individualized training exercises. The steering unit counts down 60 minutes visible for the patient

Device: Multifocal TENS garment (Mollii®)
Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
Other Names:
  • Mollii®
  • Elektrodress
  • Swedish patent:SE534365.C2
  • Sham Comparator: Sham treatment

    Use of the garment Mollii® (Elektrodress) but without the electrical stimulation combined with the individualized training exercises. The steering unit counts down 60 minutes visible for the patient

    Device: Multifocal TENS garment (Mollii®)
    Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
    Other Names:
  • Mollii®
  • Elektrodress
  • Swedish patent:SE534365.C2
  • Outcome Measures

    Primary Outcome Measures

    1. Goal attainment scaling (GAS) [12 weeks]

      1 to 3 goals are defined and evaluated using the original GAS scale by Kiresuk

    2. Arm-hand ability (ARAT + WMFT tasks 1&2) [12 weeks]

      Action Research Arm Test (ARAT)measuring grasp, grip, pinch and gross movement and this is complemented by Wolf Motor Function Test (WMFT) tasks 1 and 2 measuring active shoulder abduction

    3. Mobility [12 weeks]

      10 meter walking test, divided into comfortable gait test (CGT) and fast gait test (FGT). Outcome is velocity, cadence and stride length. Timed Up & Go (TUG)

    Secondary Outcome Measures

    1. Health related Quality of Life/QALY [Baseline, week 6, 12, 18, 52]

      SF-36 and EQ-VAS

    2. Self reported pain and spasticity [Baseline, week 6, 12, 18, 52]

      Numeric rating scale (NRS)

    3. Muscle hypertonicity (Spasticity) [Baseline, week 6, 12, 18, 52]

      Modified Ashworth scale (0-5)

    4. Range of Motion [Baseline, week 6, 12, 18, 52]

      Goniometer

    5. Costs [Baseline, week 6, 12, 18, 52]

      Costs directly related to intervention Baseline, week 6, 12, 18 Costs from a societal perspective at baseline and week 52

    6. Goal Attainment Scaling (GAS) [52 weeks]

      1 to 3 goals are defined and evaluated using the original GAS scale by Kiresuk

    7. Arm-hand ability (ARAT + WMFT tasks 1&2) [52 weeks]

      Action Research Arm Test (ARAT)measuring grasp, grip, pinch and gross movement and this is complemented by Wolf Motor Function Test (WMFT) tasks 1 and 2 measuring active shoulder abduction

    8. Mobility [52 weeks]

      10 meter walking test, divided into comfortable gait test (CGT) and fast gait test (FGT). Outcome is velocity, cadence and stride length. Timed Up & Go (TUG)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Spasticity due to stroke or Cerebral Palsy

    • Have some preserved walking ability, with or without walking aids

    • Be able to understand the treatment and instruments/interviews used

    • For stroke participants, two years should have elapsed since their injury/insult

    Exclusion Criteria:
    • Electronic devices

    • Ventriculoperitoneal shunt

    • Arrhythmia

    • Hearth infarction or unstable angina pectoris

    • Symptomatic hyper- or hypotonia

    • Cancer under treatment

    • Unstable psychiatric disease

    • Lung disease, affecting daily life

    • Unstable epileptic disease

    • Orthopedic surgery last year

    • Obesity with BMI > 35

    • Infectious disease with longstanding treatment

    • Pregnancy

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Linkoeping University
    • University of Borås
    • University Hospital, Linkoeping
    • Sodra Alvsborgs Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Per Ertzgaard, M.D., Linkoeping University
    ClinicalTrials.gov Identifier:
    NCT02261142
    Other Study ID Numbers:
    • LIU-ED2013
    First Posted:
    Oct 10, 2014
    Last Update Posted:
    Jul 13, 2015
    Last Verified:
    Jul 1, 2015
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 13, 2015